Letter from the CEO
As we start 2022, I thought it a good opportunity to review some of the important events of 2021 and discuss our most recent progress.The pandemic has during 2021 continued to play a role but even with the effects of Covid, it has still been a year including many milestones for SciBase. SciBase Strategy, MDR and NMSC SciBase’s strategy is based on gaining traction for our melanoma detection test in key markets and leveraging our core technology Electrical Impedance Spectroscopy (EIS) in additional clinical applications. Each new application uses the same core EIS technology but